Action Taken: Responding to changing market dynamics and company performance, analysts update their recommendations. Whether ...

The market expects CVRx (CVRX) to deliver a year-over-year increase in earnings on higher revenues when it reports results for the quarter ended December 2024. This widely-known consensus outlook is ...

CVRx (NASDAQ:CVRX – Get Free Report) is expected to post its quarterly earnings results before the market opens on Thursday, ...

Cantor Fitzgerald issued their FY2025 earnings estimates for shares of CVRx in a research note issued on Tuesday, January 21st. Cantor Fitzgerald analyst R. Osborn expects that the company will post ...

William Blair analyst Margaret Kaczor reiterated a Buy rating on CVRx (CVRX – Research Report) on January 18 and set a price target of $17.62.

Fintel reports that on January 14, 2025, William Blair upgraded their outlook for CVRx (NasdaqGS:CVRX) from Market Perform to Outperform. Analyst Price Forecast Suggests 14.74% Upside As of December ...

Craig-Hallum raised the firm’s price target on CVRx (CVRX) to $22 from $20 and keeps a Buy rating on the shares. CVRx posted a modest beat in ...

CVRx CVRX has been analyzed by 6 analysts in the last three months, revealing a diverse range of perspectives from bullish to bearish. The following table provides a quick overview of their recent ...

The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations ...

CVRx is focused on the development and commercialization of the Barostim™ System, the first medical technology approved by FDA that uses neuromodulation to improve the symptoms of heart failure.

In the latest quarter, 7 analysts provided ratings for CVRx (NASDAQ:CVRX), showcasing a mix of bullish and bearish perspectives. The table below summarizes their recent ratings, showcasing the ...

The market expects CVRx (CVRX) to deliver a year-over-year increase in earnings on higher revenues when it reports results for the quarter ended December 2024. This widely-known consensus outlook ...